Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Bauer

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
RMD Open|March 17, 2022
Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd studyDésirée van der Heijde, Lianne S Gensler, Walter P Maksymowych, et al.
Rheumatology and Therapy|June 13, 2020
Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISERobert Landewé, Désirée van der Heijde, Maxime Dougados, et al.
BMC Neurology|May 22, 2009
MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndromeJessica M Nielsen, Christoph Pohl, Chris H Polman, et al.
Therapeutic Advances in Musculoskeletal Disease|April 15, 2021
Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW studyIrene E van der Horst-Bruinsma, Rianne E van Bentum, Frank D Verbraak, et al.
RMD Open|May 7, 2020
The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEWIrene van der Horst-Bruinsma, Rianne van Bentum, Frank D Verbraak, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial SpondyloarthritisAtul Deodhar, Lianne S Gensler, Jonathan Kay, et al.
Annals of the Rheumatic Diseases|May 9, 2020
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reductionRobert Bm Landewé, Désirée van der Heijde, Maxime Dougados, et al.
Lancet (London, England)|August 7, 2007
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT studyLudwig Kappos, Mark S Freedman, Chris H Polman, et al.
Journal of Neurology|November 16, 2007
Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1bChris Polman, Ludwig Kappos, Mark S Freedman, et al.
RMD Open|March 21, 2018
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritisDésirée van der Heijde, Atul Deodhar, Oliver FitzGerald, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
RMD Open|March 17, 2022
Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd studyDésirée van der Heijde, Lianne S Gensler, Walter P Maksymowych, et al.
Rheumatology and Therapy|June 13, 2020
Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISERobert Landewé, Désirée van der Heijde, Maxime Dougados, et al.
BMC Neurology|May 22, 2009
MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndromeJessica M Nielsen, Christoph Pohl, Chris H Polman, et al.
Therapeutic Advances in Musculoskeletal Disease|April 15, 2021
Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW studyIrene E van der Horst-Bruinsma, Rianne E van Bentum, Frank D Verbraak, et al.
RMD Open|May 7, 2020
The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEWIrene van der Horst-Bruinsma, Rianne van Bentum, Frank D Verbraak, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial SpondyloarthritisAtul Deodhar, Lianne S Gensler, Jonathan Kay, et al.
Annals of the Rheumatic Diseases|May 9, 2020
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reductionRobert Bm Landewé, Désirée van der Heijde, Maxime Dougados, et al.
Lancet (London, England)|August 7, 2007
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT studyLudwig Kappos, Mark S Freedman, Chris H Polman, et al.
Journal of Neurology|November 16, 2007
Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1bChris Polman, Ludwig Kappos, Mark S Freedman, et al.
RMD Open|March 21, 2018
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritisDésirée van der Heijde, Atul Deodhar, Oliver FitzGerald, et al.
Pageof 5